A G4, P1, L0 female comes for antenatal checkup at 12 weeks of gestation. She has had two prior 1st trimester surgical MTPs, and delivered a 7 month boy in her last pregnancy who died 14 days after birth due to jaundice. She reveals that her blood group is B negative and that she was monitored with repeated blood tests in her last pregnancy. There is no history of anti-D administration. True regarding her management is:

**Core Concept**
The patient's history of previous pregnancies, including a prior stillbirth at 7 months due to jaundice, suggests a possible hemolytic disease of the newborn (HDN) caused by RhD incompatibility. However, the patient's blood group is B negative, which should be RhD negative. The lack of anti-D administration in her previous pregnancy raises concerns about potential RhD sensitization.

**Why the Correct Answer is Right**
The patient's previous stillbirth and history of multiple pregnancies suggest a potential risk of RhD sensitization, which could be due to the presence of RhD-positive fetal red cells in her circulation during pregnancy. As an RhD-negative individual, she would develop anti-D antibodies if exposed to RhD-positive fetal red cells. These antibodies can cross the placenta and cause hemolysis in RhD-positive fetuses, leading to potentially life-threatening jaundice and kernicterus. The lack of anti-D administration in her previous pregnancy increases the risk of RhD sensitization.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because it does not address the patient's risk of RhD sensitization and its potential consequences on her future pregnancies.

**Option B:** This option is incorrect because it does not provide a clear plan for managing the patient's risk of RhD sensitization and its potential consequences on her future pregnancies.

**Option C:** This option is incorrect because it does not address the patient's risk of RhD sensitization and its potential consequences on her future pregnancies, and it does not provide a clear plan for managing her condition.

**Option D:** This option is incorrect because it does not provide a clear plan for managing the patient's risk of RhD sensitization and its potential consequences on her future pregnancies.

**Clinical Pearl / High-Yield Fact**
In RhD-negative individuals, repeated exposure to RhD-positive fetal red cells can lead to the development of anti-D antibodies, which can cause hemolysis in RhD-positive fetuses. Administration of anti-D immunoglobulin (Rh immune globulin) during pregnancy and after delivery can prevent RhD sensitization.

**Correct Answer: D. Administer anti-D immunoglobulin (Rh immune globulin) at 28 weeks of gestation and after delivery to prevent RhD sensitization.**

✓ Correct Answer: A. Monitor the pregnancy with MCA PSV values